Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

Fig. 1

Flow diagram illustrating the methods to retrospectively compare the efficacy of osimertinib (OSI) versus afatinib (AFA) in patients with T790M-positive, non-small-cell lung cancer (NSCLC) and multiple central nervous system (CNS) metastases after failure of initial epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us